Curative Biotechnology Stock Book Value Per Share

CUBT Stock  USD 0.02  0.0007  4.46%   
Curative Biotechnology fundamentals help investors to digest information that contributes to Curative Biotechnology's financial success or failures. It also enables traders to predict the movement of Curative Stock. The fundamental analysis module provides a way to measure Curative Biotechnology's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Curative Biotechnology stock.
Last ReportedProjected for Next Year
Book Value Per Share(0.01)(0.01)
Tangible Book Value Per Share(0.01)(0.01)
Book Value Per Share is likely to drop to -0.0057 in 2025. Tangible Book Value Per Share is likely to drop to -0.0083 in 2025.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Curative Biotechnology Company Book Value Per Share Analysis

Curative Biotechnology's Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.

Book Value per Share

 = 

Common Equity

Average Shares

More About Book Value Per Share | All Equity Analysis

Current Curative Biotechnology Book Value Per Share

    
  (0) X  
Most of Curative Biotechnology's fundamental indicators, such as Book Value Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Curative Biotechnology is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Curative Book Value Per Share Driver Correlations

Understanding the fundamental principles of building solid financial models for Curative Biotechnology is extremely important. It helps to project a fair market value of Curative Stock properly, considering its historical fundamentals such as Book Value Per Share. Since Curative Biotechnology's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Curative Biotechnology's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Curative Biotechnology's interrelated accounts and indicators.
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.
Competition

Curative Common Stock Shares Outstanding

Common Stock Shares Outstanding

461.04 Million

At this time, Curative Biotechnology's Common Stock Shares Outstanding is comparatively stable compared to the past year.
In accordance with the recently published financial statements, the book value per share of Curative Biotechnology is about -0.003 times. This is 99.82% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The book value per share for all United States stocks is 100.0% higher than that of the company.

Curative Book Value Per Share Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Curative Biotechnology's direct or indirect competition against its Book Value Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Curative Biotechnology could also be used in its relative valuation, which is a method of valuing Curative Biotechnology by comparing valuation metrics of similar companies.
100%
Curative Biotechnology is currently under evaluation in book value per share category among its peers.

Curative Biotechnology Current Valuation Drivers

We derive many important indicators used in calculating different scores of Curative Biotechnology from analyzing Curative Biotechnology's financial statements. These drivers represent accounts that assess Curative Biotechnology's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Curative Biotechnology's important valuation drivers and their relationship over time.
202020212022202320242025 (projected)
Market Cap9.9M26.1M11.4M14.1M12.7M13.3M
Enterprise Value10.3M25.4M12.5M16.3M14.7M15.4M

Curative Fundamentals

Return On Equity-3.98
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-1,000%-500%0%500%1,000%1,500%2,000%
Return On Asset-0.52
Current Valuation16.08 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-310%100%200%300%400%
Shares Outstanding903.26 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-3120%40%60%80%100%120%140%
Shares Owned By Insiders0.05 %
Price To Sales158.53 X
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-310%10%20%30%
Revenue132.32 K
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-100%-80%-60%-40%-20%
Gross Profit100.21 K
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-1,000%-800%-600%-400%-200%
EBITDA(2.5 M)
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-140,000%-120,000%-100,000%-80,000%-60,000%-40,000%-20,000%
Net Income(3.96 M)
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-310%5,000%10,000%15,000%20,000%25,000%30,000%
Cash And Equivalents126.85 K
Total Debt2.26 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-310%200%400%600%800%1,000%1,200%
Debt To Equity6.60 %
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-100%-50%0%50%100%
Current Ratio0.10 X
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-100%0%100%200%300%
Book Value Per Share(0) X
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-310%500%1,000%1,500%
Cash Flow From Operations(486.58 K)
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-100%0%100%200%300%
Earnings Per Share(0.01) X
Beta-19.39
Market Capitalization14.81 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-100%0%100%200%300%400%
Total Asset2.6 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-310%1,000%2,000%3,000%4,000%
Retained Earnings(38.23 M)
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31200%400%600%800%
Working Capital(4.42 M)
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31
Net Asset2.6 M

About Curative Biotechnology Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Curative Biotechnology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Curative Biotechnology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Curative Biotechnology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Curative Stock Analysis

When running Curative Biotechnology's price analysis, check to measure Curative Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Curative Biotechnology is operating at the current time. Most of Curative Biotechnology's value examination focuses on studying past and present price action to predict the probability of Curative Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Curative Biotechnology's price. Additionally, you may evaluate how the addition of Curative Biotechnology to your portfolios can decrease your overall portfolio volatility.